New Data Show Efficacy of Zebinix(TM) in the Treatment o... (-2093-302 Study. Abstract and oralcommun...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy

Date:9/24/2008

-2093-302 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(4). Lopes-Lima J, Gil-Nagel A, Maia J et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(5). Cramer J, Maia J, Almeida L, Soares-da-Silva P. Quality-of-life improvement during long-term treatment with eslicarbazepine acetate. Abstract and poster, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(6). Hodoba D, CzÃ…â€šonkowska A, Cramer J. Depressive symptoms improvement during long-term treatment with eslicarbazepine acetate. Abstract and poster, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(7). Guekht A, Elger C, Halasz P et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate: results of a 1-year open-label extension study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(8). WHO Atlas: Epilepsy Care in the World. WHO 2005

(9). Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001;42(Suppl 3):27-30

(10). Mei PA, Montenegro MA, Guerreiro MM, Guerreiro CA. Pharmacovigilance in epileptic patients using antiepileptic drugs. Arq Neuropsiquiatr 2006 Jun;64(2A): 198-201. Epub 2006 Jun 9

For more information please contact:

BIAL (head office)

Francisco Osorio

Tel.: +351-22-986-6100

Mobile: +351-96-346-9968

francisco.osorio@bial.com

Paul Gittins

Red Health

Tel.: +44-207-025-6571

Mobile: +44-7958-533-462

SOURCE BIAL
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
2. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
3. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
4. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
7. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
11. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

Post Your Comments:

(Date:11/9/2009)...PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc...ults from the Company,s Bepreve(TM) (bepotastine b... studies. These results were presented in poster ...n College of Allergy, Asthma & Immunology (ACA...ation titled, "Treatment of Ocular Itching with Be...

(Date:11/9/2009)...., Nov. 9 Thomson Reuters today ... CareFocus, a leading clinical surveillance soluti...ents in real-time and respond immediately to impro...ment. ,, This upgrade is available to current C...CareFocus 2.0 contains several powerful enhancemen...

(Date:11/9/2009)...ov. 9 Arcadia Resources,...novative consumer health care services under the A... Goldsmith to its Board of Directors. Goldsmith w...n from the Board. ,, (Photo: http://www.ne...Goldsmith is the Daniel Paul Professor of Governme...

[0] ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)[0] Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs [0] Arcadia Resources Names Stephen Goldsmith to Board of Directors

...l 17 The SurgiLance safety lancet,an industry-lea...rpose, has,been selected for inclusion in an HIV k... Bundi International Diagnostics. Long established...cets are now part of a major,testing initiative de...,continent., A critical component of the fight ag...

...onstrate Predictable, Extended Exposure with Susta..., CHICAGO, April 17 Data from the first pivotal ...nvestigational compound to treat,Restless Legs Syn... the,symptoms of moderate-to-severe primary RLS co...d when administered once-daily for 12 weeks., Dat...

Other Medicine Technology:SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa 2 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6

SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

(Date:11/9/2009)... SHENZHEN, China, Nov. 9 /PRNewswire-Asia-FirstC...E: MR ), a leading developer, manufacturer and,ma...ay its selected unaudited,financial results for th...,2009. , , Highlights for Operations as of Se...enues were $151.1 million, an increase of, 3...

(Date:11/9/2009)...House action backs President Obama,s promise to no... example ,, Bishops still concerned for poor,...ewswire/ -- Cardinal Francis George of Chicago, pr...c Bishops, lauded the November 7 decision of the U...th care reform money from paying for elective abor...

(Date:11/9/2009)... Studying Genetic Variance Acros...ts of Genes , (Vocus) Nov...estries can be extraordinarily valuable when analy...ti-center genetics study that scanned the genome...r regional differences, Drs. Chao Tian and Michael...

(Date:11/9/2009)... implanted with new cells regained sexual function...lthDay News) -- Researchers were able to restore s...growing new penile tissue in the lab and implantin...lication is a ways off, researchers say the techni... dysfunction in men. , "We were able to show th...

(Date:11/9/2009)... Course, to be Offered in April ...olkit , Cambridge, MA (Vo...ysicians for Human Rights (PHR) first inspected a ...tan , he realized he would need a team of experts ...ing the site properly was a key first step in secu...

[0] Mindray Announces Third Quarter 2009 Financial Results [0] Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly [0] News from the November/December Issue of Molecular Medicine [0] Scientists Grow New Penile Tissue in the Lab [2] Physicians for Human Rights Offers Training in Crime Scene Documentation

...y 6 Carriage Services, Inc. (NYSE: CSV ) today ...h 31, 2009. Highlights from continuing operations...st quarter of 2008 were as follows: , , First Qu... 2008 2009 Change, ...

...Tenn., May 6 TeamHealth Inc.,s parent company, Te...sults for the first quarter of 2009. , , Net re...less provision") in the first quarter of 2009 incr... $319.0 million from $305.5 million in the same pe...

... stents should discuss the use of these meds with ...SDAY, May 6 (HealthDay News) -- Anyone who takes t...tent in a coronary artery-opening procedure should...cid reflux medications such as Nexium, Prevacid an...

...ns emphasize need for improved mental health servi... The Regence Foundation announced today it awarded...es in Idaho, Oregon, Utah and Washington. Five of ...ted transformation grant program. , , "Encouragin...

...f those hospitalized in U.S. is 15, CDC says , ...the large majority of U.S. cases continue to be mi...disease appear to be atypically young, health offi..., U.S. Centers for Disease Control and Prevention ...

...ELEY, Calif., May 6 The following was released ...new report from the National Institute for Occu...in Las Vegas casinos are exposed to dangerous leve... , In 2005, blackjack dealers working in three Las...

Carriage Services Announces First Quarter 2009 Results Team Finance LLC Announces First Quarter 2009 Results Plavix, Heartburn Drugs May Be Risky Combination Regence Foundation Grants $390,000 to Improve Health Care Safety Net Younger Age of Severe Swine Flu Cases Worries Experts No Safe Bets for Casino Workers: NIOSH Study Shows Casino Workers Face Toxic Conditions

Creatine Kinase Reagent

Creatine Kinase-MB (CK-MB)

Magnesium Liquid Reagent

Glucose Oxidase Reagent Set (Phenol Free)

Medicine Products:

Creatine Kinase Reagent Creatine Kinase-MB (CK-MB)Magnesium Liquid Reagent Glucose Oxidase Reagent Set (Phenol Free)

New Data Show Efficacy of Zebinix(TM) in the Treatment o...(-2093-302 Study. Abstract and oralcommun...),Health